Pharmaceutical Executive
April 13, 2010
Features
0
0
The faces and names behind the year's best pharmaceutical advertising.
March 01, 2010
Issue PDF
0
0
Merck’s Man in Emerging Markets
March 01, 2010
From the Editor
0
0
Is it possible to remain commercially relevant just as a developer and distributor of drugs? Are there equivalent profits in a larger set of commitments?
March 01, 2010
Features
0
0
Pricing, promotion, and the unfinished story of healthcare reform dominated the news last year.
March 01, 2010
Strategy
0
0
In a digital world, vast quantities of data at hand are a powerful asset. Managing that information is key to seizing competitive advantage.
March 01, 2010
Washington Report
0
0
FDA's new Sentinel System is going live, but the signals may be difficult to assess.
March 01, 2010
0
0
The faces and names behind the year's best pharmaceutical advertising.
March 01, 2010
0
0
The faces and names behind the year's best pharmaceutical advertising.
March 01, 2010
0
0
The faces and names behind the year's best pharmaceutical advertising.
March 01, 2010
Features
0
0
Several leading pharmas may already have a drug for a retrovirus linked to chronic fatigue disease. Has medicine's "problem child" finally earned the industry's respect?
March 01, 2010
0
0
The faces and names behind the year's best pharmaceutical advertising.
March 01, 2010
0
0
The faces and names behind the year's best pharmaceutical advertising.
March 01, 2010
Columns
0
0
Pharma companies need a clear online policy that addresses employee obligations, monitoring guidelines, and engagement roles.
March 01, 2010
Regulatory
0
0
Obligations to fund and support costly studies can extend beyond the period of market exclusivity, giving generics competitors an advantage.
March 01, 2010
0
0
The faces and names behind the year's best pharmaceutical advertising.
March 01, 2010
0
0
The faces and names behind the year's best pharmaceutical advertising.
March 01, 2010
Back Page
0
0
Here are five pharmaceutical advertisement parodies that will make you howl 'till it hurts.
March 01, 2010
Features
0
0
Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world?